Evidence map›Paper›PMID 18166300›Full record

Trial reportAmerican journal of obstetrics and gynecology2008

Do short-term markers of treatment efficacy predict long-term sequelae of pelvic inflammatory disease?

Gail M Trautmann, Kevin E Kip, Holly E Richter, David E Soper, Jeffrey F Peipert, Deborah B Nelson, Wayne Trout, Dianne Schubeck, Debra C Bass, Roberta B Ness

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in American journal of obstetrics and gynecology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Gail M TrautmannUniversity of Pittsburgh School of Public Health, Pittsburgh, PA 15261, USA.
Kevin E Kip
Holly E Richter
David E Soper
Jeffrey F Peipert
Deborah B Nelson
Wayne Trout
Dianne Schubeck
Debra C Bass
Roberta B Ness
University of Pittsburgh · USMedical University of South Carolina · USMetroHealth Medical Center · USThe Ohio State University · USUniversity of Alabama at Birmingham · USUniversity of Pennsylvania · USWashington University in St. Louis · US

Funding

Effectiveness of Outpatient Treatment of PIDR01AI048909 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NESS, ROBERTA B. · 2001 to 2003
$1.8M
EFFECTIVENESS OF OUTPATIENT TREATMENT OF PIDR21AI048909 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NESS, ROBERTA B. · 2000 to 2000
$447k
EFFECTIVENESS OF OUTPATIENT TREATMENT FOR PIDR01HS008358 · AHRQ · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NESS, ROBERTA B. · 1995 to 1999
–
AHRQ HHS HS08358-05AHRQ HHS R01 HS008358NIAID NIH HHS AI 48909-07NIAID NIH HHS R01 AI048909
6 · The paper itself

Abstract

objectiveThis study was undertaken to assess whether short-term markers, often used to measure clinical cure after treatment for pelvic inflammatory disease, predict sequelae of lack of pregnancy, recurrent pelvic inflammatory disease, and chronic pelvic pain. STUDY

designWomen with mild-to-moderate pelvic inflammatory disease were assessed after treatment initiation at 5 days for tenderness (n = 713) and at 30 days for tenderness, cervical infections and endometritis (n = 298). Pregnancy, recurrent pelvic inflammatory disease, and chronic pelvic pain were evaluated after 84 months, on average.

resultsPelvic tenderness at 5 and at 30 days significantly elevated the risk for developing chronic pelvic pain; tenderness at 30 days was also significantly associated with recurrent pelvic inflammatory disease. However, pelvic tenderness at 5 and at 30 days was only modestly clinically predictive of chronic pelvic pain or recurrent pelvic inflammatory disease (positive predictive values 22.1-66.9%). No short-term marker significantly influenced the likelihood of achieving a pregnancy.

conclusionTenderness at 5 or 30 days did not accurately predict the occurrence of pelvic inflammatory disease-related reproductive morbidities.

Indexed as

Administration, OralAdolescentAdultCefoxitinDose-Response Relationship, DrugDoxycyclineDrug Administration ScheduleDrug Therapy, CombinationFemaleFollow-Up StudiesHumansInfertility, FemaleInflammation MediatorsInfusions, IntravenousPain MeasurementPelvic Inflammatory DiseaseCefoxitinDoxycyclineInflammation MediatorsProbenecid

Identifiers

PMID18166300
PMCPMC2330265
OpenAlexW1987497494

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.